Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mXELOX vs FOLFOX with Cetuximab in RAS/BRAF WT mCRC
NCT05074966Phase 3Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Sep 2021
- Primary completion
- Jun 2024
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in metastatic colorectal cancer (mCRC), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
capecitabine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05074966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074966.